Xintian Pharmaceutical: Announcement on the change in the controlling shareholder’s equity reaching 1% and the completion of the shareholding reduction plan

Securities code: 002873 Securities abbreviation: Xintian Pharmaceutical Announcement number: 2026-043

Guiyang Xintian Pharmaceutical Co., Ltd.

Announcement on the change in the controlling shareholder's equity reaching 1% and the completion of the shareholding reduction plan

The company's controlling shareholder, Shanghai Xintian Zhiyao Biotechnology Co., Ltd., guarantees that the information provided to the company is true, accurate and complete, and contains no false records, misleading statements or major omissions.

The company and all members of the board of directors guarantee that the content of the announcement is consistent with the information provided by the information disclosure obligor.

Guiyang Xintian Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or the "Company") disclosed the "Pre-Disclosure Announcement on the Controlling Shareholder's Plan to Reduce the Company's Shares" (Announcement No.: 2026-030) on May 8, 2026. It holds 68,435,566 shares of the company (accounting for 2026 On May 6, 2020 (the same below for this paragraph), the controlling shareholder Shanghai Xintian Zhiyao Biotechnology Co., Ltd. (hereinafter referred to as "Xintian Zhiyao") planned to reduce its holdings of the company's shares by no more than 7,050,000 through block transactions and centralized bidding transactions. shares, accounting for 2.9962% of the total share capital after excluding the shares in the company's special account for repurchase (including: no more than 4,700,000 shares of the company's shares were reduced through block transactions, accounting for 6.8678% of the total number of company shares held, accounting for 1.9975% of the total share capital after excluding the shares in the company's special account for repurchase; no more than 2,350,000 of the company's shares were reduced through centralized bidding transactions. shares, accounting for 3.4339% of the total number of shares it holds in the company, accounting for 0.9987% of the total share capital after excluding the shares in the company’s special repurchase account).

On May 7, 2026, the company sold 789,800 repurchased shares for the first time in a centralized bidding transaction. The share capital after excluding the shares in the company's special repurchase account increased from 235,297,776 shares to 236,087,576 shares. shares, the company's controlling shareholder Xintian Zhiyao, while the number of shares held remains unchanged, the proportion of its shares held in the share capital after excluding the shares in the company's special repurchase account was passively diluted from 29.0847% to 28.9874%, and the change in equity touched 1%. For details, please refer to the "Announcement on the Passive Dilution of the Controlling Shareholder's Shareholding Ratio Touching 1%" disclosed by the company on May 9, 2026 (Announcement Number: 2026-031).

As of May 12, 2026, the company has sold a total of 2,441,000 repurchased shares through centralized bidding transactions (including 789,800 shares sold for the first time on May 7, 2026). The share capital after excluding the shares in the company's special repurchase account increased from 236,087,576 shares on May 7, 2026 to 237,738,776 shares, the company's controlling shareholder Xintian Zhiyao, while the number of shares held remains unchanged, the proportion of its shareholdings in the share capital after excluding the shares in the company's special account for repurchase has been passively diluted from 28.9874% to 28.7860%.

From June 8, 2026 to July 31, 2026, Xintian Intelligent Medicine reduced its holdings by a total of 2,300,000 through centralized bidding transactions and block transactions. shares, the proportion of its shareholding in the capital after excluding the shares in the company's special repurchase account has changed from 28.7860% to 27.8186%, and the change in equity has touched 1%. For details, please refer to the "Announcement on the Change in the Controlling Shareholder's Equity Touching 1%" disclosed by the company on August 4, 2026 (Announcement Number: 2026-041).

Recently, the company received the "Notification Letter of Reducing the Number of Shares Reduced to 1% and the Implementation of the Share Reduction Plan" issued by Xintian Intelligent Pharmaceutical. From August 3 to August 6, 2026, Xintian Intelligent Pharmaceutical reduced its holdings of the company's shares by a total of 4,655,000 through centralized bidding and block transactions. shares, the proportion of its shareholdings in the total share capital after excluding the shares in the company's special repurchase account dropped from 27.8186% to 25.8606%, and the change in equity touched 1%. As of the disclosure date of this announcement, this shareholding reduction plan has been completed. The specific situation is as follows:

1. The situation where the change ratio of controlling shareholder’s equity reaches 1%

1． Basic situation

Information disclosure obligor Shanghai Xintian Zhiyao Biotechnology Co., Ltd.

Residence: Room 1040, 10th floor, No. 390-408, Beijing East Road, Huangpu District, Shanghai

Equity change time: August 3, 2026 - August 6, 2026

The company's controlling shareholder, Shanghai Xintian Zhiyao Biotechnology Co., Ltd., reduced its holdings of the company's shares through centralized bidding transactions and block transactions from August 3, 2026 to August 6, 2026, and the cumulative equity changes reached 1%.

Stock abbreviation Xintian Pharmaceutical Stock code 002873

Direction of change Up□ Down■ Persons acting in concert Yes□ No■

Is it the largest shareholder or actual controller? Yes ■ No □

2. Changes in equity this time

Number of shares reduced as a percentage of total share capital Number of shares reduced as a proportion of total shares Type of shares (A shares, B shares, etc.) Number of shares reduced (shares)

Proportion (after excluding shares in the special repurchase account) A shares

4,655,000 1.9070% 1.9580%

total

4,655,000 1.9070% 1.9580%

Centralized trading through stock exchanges ■

The method of this equity change is through block trading on the stock exchange ■

Others □

3． Before and after this change, investors and their persons acting in concert have shares in listed companies.

Shares held before this change. Shares held after this change.

Proportion of total share capital Proportion of total share capital Nature of shares

Share of total share capital Example (excluding repurchase shares) Share of total share capital (excluding repurchase shares (shares) Number of shares (shares)

Proportion of purchasing special account Proportion of using shares in the account

After winning shares) After) Total shares held 66,135,566 27.0932% 27.8186% 61,480,566 25.1862% 25.8606%

Including: shares without selling restrictions 66,135,566 27.0932% 27.8186% 61,480,566 25.1862% 25.8606%

Restricted shares 0 0 0 0 0 0

4． Implementation of commitments, plans, etc.

Yes ■ No □ If yes, please explain the details of the commitment, intention, plan and implementation progress.

The company disclosed the "Pre-Disclosure Announcement Regarding the Controlling Shareholder's Plan to Reduce the Company's Shares" on May 8, 2026 (Announcement No.: 2026-030), holding 68,435,566 shares of the company (accounting for 2026 On May 6, 2020 (the same below for this paragraph), the controlling shareholder Xintian Zhiyao plans to make this change through bulk transactions and centralized bidding transactions, excluding 29.0847% of the total share capital after excluding the shares in the company's special repurchase account.

The total number of shares held by the company shall not exceed 7,050,000 shares, excluding the company's commitments, intentions and plans for repurchase.

The proportion of the total share capital after the shares in the account is 2.9962% (including: the reduction of the company's shares by no more than 4,700,000 shares through block transactions, accounting for 6.8678% of the total number of company shares held by it, accounting for the total share capital after excluding the shares in the company's special account for repurchase. 1.9975% of the share capital; through centralized bidding transactions, the company's shares are reduced by no more than 2,350,000 shares, accounting for 3.4339% of the total number of company shares it holds, accounting for 0.9987% of the total share capital after excluding the shares in the company's special repurchase account).

As of the disclosure date of this announcement, the holding reduction by the controlling shareholder Xintian Zhiyao is consistent with the previously disclosed shareholding reduction plan and related commitments. The quantity and method of reduction are in line with the disclosed shareholding reduction plan.

It is agreed that the above-mentioned reduction plan has been completed.

Whether this change violates the "certificate"

Securities Law "Acquisition Management of Listed Companies"

Yes□ No■

Measures and other laws, administrative regulations,

If so, please describe the specific circumstances of the violation, rectification plan and handling measures. Department regulations, normative documents and this

Situations stipulated in business rules, etc.

5. Shares with restricted voting rights

In accordance with Article 63 of the Securities Law

Yes□ No■

stipulations, whether they exist or not, shall not be exercised

If so, please indicate the corresponding number of shares and their proportion to the share capital of the existing listed company. voting shares

2. Implementation of the controlling shareholder’s shareholding reduction plan

1. Shareholding reduction plan of shareholders this time

The average shareholding reduction is the ratio of the shares reduced to the total equity of the company.

Reduce holdings Reduce number of shares

Name of shareholder Shareholding reduction period Price (yuan/total share capital of the company) Example (excluding the method in the special account for repurchase (shares)

Shares) Ratio Shares after) Concentration

Bid 7.63 700,000 0.2868% 0.2944% Transaction 2026.6.8

—

Bulk 2026.7.31

7.49 1,600,000 0.6555% 0.6730%Shanghai Xintianzhi Transaction

Pharmaceutical Biotechnology

Concentrate

Ltd.

Bid 7.84 1,650,000 0.6759% 0.6940% Transaction 2026.8.3

—

Bulk 2026.8.6

7.19 3,005,000 1.2310% 1.2640% Transaction

Total - - 6,955,000 2.8492% 2.9255% Note: 1. The relevant proportions in the above table are calculated according to the proportion of the reduction of holdings in the company's total share capital. If the sum of the mantissas does not match, it is due to rounding;

2. The company’s latest total share capital is 244,103,806 shares. After excluding the shares in the special account for repurchase, the company’s total share capital is 237,738,776 shares;

3. The company disclosed the "Announcement on the 1% Change in Controlling Shareholder's Equity" (Announcement No.: 2026-041) on August 4, 2026. The average shareholding reduction price, number of shares reduced and their proportion in the above table from 2026.6.8 to 2026.7.31 and other relevant information on shareholding reduction are quoted from this announcement.

4. Shareholding status of shareholders before and after the implementation of this shareholding reduction plan

Shares held before the implementation of the shareholding reduction plan. Shares held after the implementation of the shareholding reduction plan.

Share of total share capital Share of total share capital Name of shareholder

Nature of shares Proportion (tick) Ratio (tick) Share of total share capital Share of total share capital

Number of shares (shares) Excluding repurchases Number of shares (shares) Excluding repurchases ratio Ratio

After using the shares in the account) After using the shares in the account)

Total shares held 68,435,566 28.0354% 29.0847% 61,480,566 25.1862% 25.8606% Xintianzhi

Shares without selling restrictions 68,435,566 28.0354% 29.0847% 61,480,566 25.1862% 25.8606% Pharmaceutical

Restricted shares 0 0 0 0 0 0

Note: 1. The proportion of shares held before this shareholding reduction to the total share capital (after excluding the shares in the special repurchase account) is the data of the "Pre-Disclosure Announcement on the Controlling Shareholder's Plan to Reduce the Company's Shares" disclosed by the company on May 8, 2026 (Announcement No.: 2026-030) , the company's total share capital is 244,103,806 shares. As of May 6, 2026, the number of shares in the company's special account for repurchasing shares is 8,806,030 shares. After excluding the shares in the special account for repurchase, the total share capital is 235,297,776 shares.

2. The proportion of shares held in the total share capital after this reduction (after excluding the shares in the special account for repurchase) is the latest data. The company's total share capital is 244,103,806 shares. The number of shares in the company's special account for repurchase is 6,365,030 shares. The total share capital after excluding the shares in the special account for repurchase is 237,738,776 shares.

3. Other related instructions

1. During this share reduction period, the company’s controlling shareholder Xintian Zhiyao strictly complied with the provisions of the Securities Law of the People’s Republic of China, the Measures for the Administration of Acquisitions of Listed Companies, the Interim Measures for the Management of Share Reductions by Shareholders of Listed Companies, the Shenzhen Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 18 - Reduction of Shares by Shareholders, Directors and Senior Management and other relevant laws, regulations and normative documents.

2. There is no violation of relevant intentions and commitments in this shareholding reduction. The price of Xintian Intelligent Medicine’s shareholding reduction is determined based on the market price.

3. As of the date of this announcement, Xintian Intelligent Pharmaceuticals has implemented its shareholding reduction in strict accordance with the disclosed shareholding reduction plan, and there has been no violation of the disclosed shareholding reduction plan.

4. The implementation of this shareholding reduction plan will not result in a change in the company's control, nor will it have a significant impact on the company's governance structure, equity structure and ongoing operations.

4. Documents for reference

1. "Notification letter of reduction of shareholding reaching 1% and completion of shareholding reduction plan" issued by controlling shareholder Xintian Zhiyao;

2. Details of changes in shareholdings of China Securities Depository and Clearing Co., Ltd.

Announcement is hereby made.

Board of Directors of Guiyang Xintian Pharmaceutical Co., Ltd.

August 7, 2026